Next Article in Journal
Entomopathogenic Fungi Biodiversity in the Soil of Three Provinces Located in Southwest China and First Approach to Evaluate Their Biocontrol Potential
Next Article in Special Issue
COVID-19-Associated Pulmonary Aspergillosis in Russia
Previous Article in Journal
Antifungal Resistance in Dermatophytes: Genetic Considerations, Clinical Presentations and Alternative Therapies
Previous Article in Special Issue
COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors
 
 
Article

Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis

1
Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
2
Department of Public Health, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
3
Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool St, Hobart, TAS 7000, Australia
4
International Clinical Research Center, Molecular Control of Cell Signaling Group, St. Anne’s University Hospital, 656 91 Brno, Czech Republic
*
Author to whom correspondence should be addressed.
Academic Editor: Katrien Lagrou
J. Fungi 2021, 7(11), 985; https://doi.org/10.3390/jof7110985
Received: 25 October 2021 / Revised: 16 November 2021 / Accepted: 17 November 2021 / Published: 18 November 2021
(This article belongs to the Special Issue When Viruses and Fungi Act Together)
Mucormycosis, a secondary fungal infection, gained much attention in the ongoing COVID-19 pandemic. This deadly infection has a high all-cause mortality rate and imposes a significant economic, epidemiological, and humanistic burden on the patients and healthcare system. Evidence from the published epidemiological studies showed the varying prevalence of COVID-19-associated mucormycosis (CAM). This study aims to compute the pooled prevalence of CAM and other associated clinical outcomes. MEDLINE, Embase, Cochrane COVID-19 Study Register, and WHO COVID-19 databases were scanned to retrieve the relevant articles until August 2021. All studies reporting the prevalence of mucormycosis among COVID-19 patients were eligible for inclusion. Two investigators independently screened the articles against the selection criteria, extracted the data, and performed the quality assessment using the JBI tool. The pooled prevalence of CAM was the primary outcome, and the pooled prevalence of diabetes, steroid exposure, and the mortality rate were the secondary outcomes of interest. Comprehensive Meta-Analysis software version 2 was used for performing the meta-analysis. This meta-analysis comprised six studies with a pooled sample size of 52,916 COVID-19 patients with a mean age of 62.12 ± 9.69 years. The mean duration of mucormycosis onset was 14.59 ± 6.88 days after the COVID-19 diagnosis. The pooled prevalence of CAM (seven cases per 1000 patients) was 50 times higher than the highest recorded background of mucormycosis (0.14 cases per 1000 patients). A high mortality rate was found among CAM patients with a pooled prevalence rate of 29.6% (95% CI: 17.2–45.9%). Optimal glycemic control and the judicious use of steroids should be the approach for tackling rising CAM cases. View Full-Text
Keywords: coinfection; COVID-19; epidemiology; meta-analysis; mucormycosis; mycoses; prevalence; risk factors; systematic review coinfection; COVID-19; epidemiology; meta-analysis; mucormycosis; mycoses; prevalence; risk factors; systematic review
Show Figures

Figure 1

MDPI and ACS Style

Hussain, S.; Riad, A.; Singh, A.; Klugarová, J.; Antony, B.; Banna, H.; Klugar, M. Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis. J. Fungi 2021, 7, 985. https://doi.org/10.3390/jof7110985

AMA Style

Hussain S, Riad A, Singh A, Klugarová J, Antony B, Banna H, Klugar M. Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis. Journal of Fungi. 2021; 7(11):985. https://doi.org/10.3390/jof7110985

Chicago/Turabian Style

Hussain, Salman, Abanoub Riad, Ambrish Singh, Jitka Klugarová, Benny Antony, Hasanul Banna, and Miloslav Klugar. 2021. "Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis" Journal of Fungi 7, no. 11: 985. https://doi.org/10.3390/jof7110985

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop